Market Intelligence
Nine $1bn+ alliances were penned in February, and three exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $8.85bn collaboration with Eli Lilly to advance novel medicines in oncology and immunology.
A host of unusually high price increases for UK generics in February led the Department of Health and Social Care to issue the highest number of price concessions seen in almost three years.
As the US biosimilars market continues to evolve, Cardinal Health’s director of biosimilars Dracey Poore talks to Generics Bulletin for an exclusive Q&A.
An interactive look at pharma, medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
Surgeon burnout is not a new phenomenon, but where it once was episodic, surgeons now report that it feels more sustained. Support structures have not kept pace, said Johnson & Johnson MedTech VP Africa Wallace on the release of a new study of causes, trends and issues arising.
Surgeon burnout is not a new phenomenon, but where it once was episodic, surgeons now report that it feels more sustained. Support structures have not kept pace, said Johnson & Johnson MedTech VP Africa Wallace on the release of a new study of causes, trends and issues arising.
A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.
After nearly 30 years at NASA, Omar Hatamleh prepares for his next chapter and fourth book on AI. He told Medtech Insight AI will speed up medical breakthroughs, extend life spans and bring AGI sooner than expected but also drive job losses, erode privacy and force humans to rethink their purpose.
Recent BCG reports and interviews reveal an industry under pressure and racing to adapt through AI, new deal structures and direct-to-patient models.
Twenty biopharma leaders share predictions for 2026 – from shifting dealmaking dynamics and Asia's rise as an innovation epicenter to new frontiers in oncology, obesity and cell therapy, and AI's operational reckoning.
While investment promises appear to be in billions of dollars, industry experts remain skeptical.
Nine $1bn+ alliances were penned in January, and three exceeded $2bn. In the top alliance by deal value, RemeGen granted AbbVie exclusive global rights (excluding Greater China) to develop, manufacture, and commercialize RC148 for non-small cell lung cancer and other solid tumors.